BML-190

From Wikipedia, the free encyclopedia
Jump to: navigation, search
BML-190
BML-190.png
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C23H23ClN2O4
Molar mass 426.892
3D model (Jmol)
 NYesY (what is this?)  (verify)

BML-190 (Indomethacin morpholinylamide) is a drug used in scientific research that acts as a selective CB2 inverse agonist.[1] BML-190 is structurally derived from the NSAID indomethacin but has a quite different biological activity.[2] The activity produced by this compound is disputed, with some sources referring to it as a CB2 agonist rather than an inverse agonist;[3][4] this may reflect an error in classification, or alternatively it may produce different effects in different tissues, and more research is required to resolve this dispute.

References[edit]

  1. ^ New, DC; Wong, YH (2003). "BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates". FEBS Letters. 536 (1–3): 157–60. PMID 12586356. doi:10.1016/S0014-5793(03)00048-6. 
  2. ^ Klegeris, A; Bissonnette, CJ; McGeer, PL (2003). "Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor". British Journal of Pharmacology. 139 (4): 775–86. PMC 1573900Freely accessible. PMID 12813001. doi:10.1038/sj.bjp.0705304. 
  3. ^ Melck, D; De Petrocellis, L; Orlando, P; Bisogno, T; Laezza, C; Bifulco, M; Di Marzo, V (2000). "Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation". Endocrinology. 141 (1): 118–26. PMID 10614630. doi:10.1210/en.141.1.118. 
  4. ^ Scutt, A; Williamson, EM (2007). "Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors". Calcified tissue international. 80 (1): 50–9. PMID 17205329. doi:10.1007/s00223-006-0171-7.